Eylea prefilled syringe now available

The Eylea injection prefilled syringe is now available to order, Regeneron Pharmaceuticals announced.

The Eylea (aflibercept) 2 mg, single-dose, prefilled, sterilized syringe was approved in August to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy.

Designed to block the growth of new blood vessels and decrease the ability of fluid to pass through blood vessels in the eye, it is the only anti-VEGF approved to treat four retinal conditions with a single dose strength prefilled syringe.

The Eylea injection prefilled syringe is now available to order, Regeneron Pharmaceuticals announced.

The Eylea (aflibercept) 2 mg, single-dose, prefilled, sterilized syringe was approved in August to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy.

Designed to block the growth of new blood vessels and decrease the ability of fluid to pass through blood vessels in the eye, it is the only anti-VEGF approved to treat four retinal conditions with a single dose strength prefilled syringe.